Additional development and milestone payments receivable.

No definition available.

Name:	teva_AdditionalDevelopmentAndMilestonePaymentsReceivable
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Aggregate Upfront And Milestone Payments.

+ References

No definition available.

+ Details

Name:	teva_AggregateUpfrontAndMilestonePayments
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Agreement milestone payments.

+ References

No definition available.

+ Details

Name:	teva_AgreementMilestonePayments
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaboration partner funding reimbursements.

+ References

No definition available.

+ Details

Name:	teva_CollaborationPartnerFundingReimbursements
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Agreement Milestone Payments

+ References

No definition available.

+ Details

Name:	teva_CollaborativeAgreementMilestonePayments
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Development and launch milestone payment receivable.

+ References

No definition available.

+ Details

Name:	teva_DevelopmentAndLaunchMilestonePaymentReceivable
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Increase in development funding commitment.

+ References

No definition available.

+ Details

Name:	teva_IncreaseInDevelopmentFundingCommitment
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License agreement potential aggregate milestone payments amount.

+ References

No definition available.

+ Details

Name:	teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payment.

+ References

No definition available.

+ Details

Name:	teva_MilestonePayment
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payment receivable.

+ References

No definition available.

+ Details

Name:	teva_MilestonePaymentReceivable
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Milestone payment to be paid.

+ References

No definition available.

+ Details

Name:	teva_MilestonePaymentToBePaid
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payment percentage cap.

+ References

No definition available.

+ Details

Name:	teva_Milestonepaymentpercentagecap
Namespace Prefix:	teva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of discount rate applied to the cash flows.

+ References

No definition available.

+ Details

Name:	teva_PercentageOfDiscountRateAppliedToTheCashFlows
Namespace Prefix:	teva_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Phase 2b funding option amount.

+ References

No definition available.

+ Details

Name:	teva_Phase2bfundingoptionamount
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Phase 3 funding option amount.

+ References

No definition available.

+ Details

Name:	teva_Phase3fundingoptionamount
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Term of royalty payment.

+ References

No definition available.

+ Details

Name:	teva_TermOfRoyaltyPayment
Namespace Prefix:	teva_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_NoncashOrPartNoncashAcquisitionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

+ Details

Name:	us-gaap_OtherCommitment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 15
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-15

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-11

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 40
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481724/830-30-40-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 17A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 16
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-16

+ Details

Name:	us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-41

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483041/730-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=teva_SanofiMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_BiolojicDesignLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_RoyaltyPharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_PolpharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_EmalexBiosciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	teva_ConsiderationArrangementAxis=teva_OtherThirdPartiesMilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	teva_ConsiderationArrangementAxis=teva_FormerShareholdersMilestonePaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_BlackstoneLifeSciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_TevasApiBusinessMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_AbingworthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_AlvotechMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_MabxienceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_MedincellMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=teva_ModagMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Certain Transactions - Other Transactions - Additional Information (Detail) - USD ($) $ in Millions					1 Months Ended							3 Months Ended								6 Months Ended	12 Months Ended
	Jun. 10, 2026	Mar. 03, 2026	Jan. 11, 2026	Nov. 09, 2023	Jul. 31, 2026	May 31, 2026	Jan. 31, 2026	Dec. 31, 2025	Jan. 31, 2024	Oct. 31, 2021	Nov. 30, 2013	Jun. 30, 2026	Mar. 31, 2026	Dec. 31, 2025	Jun. 30, 2025	Mar. 31, 2025	Dec. 31, 2024	Sep. 30, 2022	Dec. 31, 2021	Jun. 30, 2026	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jun. 18, 2026	Mar. 28, 2024	Oct. 03, 2023
Noncash or Part Noncash Acquisitions [Line Items]
Percentage Of Discount Rate Applied To The Cash Flows																											8.75%
Other commitment																												$ 150
Sanofi [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment														$ 250
Sanofi [Member] \| Collaborative Arrangement [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment receivable																													$ 500
Development and launch milestone payment receivable																													$ 500
Biolojic Design Ltd [Member] \| Collaborative Arrangement [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Additional development and milestone payments receivable								$ 500						500							$ 500
Biolojic Design Ltd [Member] \| Research and Development Expense [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment									$ 10				$ 5								5
Royalty Pharma [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Collaborative agreement milestone payments			$ 500	$ 100
Phase 3 funding option amount			425
Phase 2b funding option amount			$ 75
Term of royalty payment				5 years
Reimbursement of research and development expenses incurred												$ 16
Royalty Pharma [Member] \| Maximum [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment percentage cap			130.00%
Royalty Pharma [Member] \| Minimum [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment percentage cap			100.00%
Royalty Pharma [Member] \| Research and Development Expense [Member] \| Collaborative Arrangement [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Collaborative agreement milestone payments																							$ 100
Reimbursement of research and development expenses incurred																						$ 100
Polpharma [Member]
Noncash or Part Noncash Acquisitions [Line Items]
License agreement potential aggregate milestone payments amount								$ 107
Emalex Biosciences [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Cash consideration	$ 700
Emalex Biosciences [Member] \| Other Third Parties Milestone Payment [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Agreement Milestone Payments	125
Emalex Biosciences [Member] \| Former Shareholders Milestone Payment [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Agreement Milestone Payments	$ 200
Blackstone Life Sciences [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Collaborative agreement milestone payments		$ 400
Blackstone Life Sciences [Member] \| Research and Development Expense [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Reimbursement of research and development expenses incurred												30	30
Teva's API business [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax																				$ 17	8
Abingworth [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Increase in development funding commitment							$ 50
Abingworth [Member] \| Research and Development Expense [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Collaboration partner funding reimbursements																				$ 200
Reimbursement of research and development expenses incurred												30									98	42
Alvotech [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment												154	$ 154	20							154	154	$ 154	$ 154	$ 154	$ 154
Collaborative agreement milestone payments														$ 320
mAbxience [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Collaborative agreement milestone payments												286
mAbxience [Member] \| Research and Development Expense [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment												$ 5									$ 29
Aggregate upfront and milestone payments																	$ 15					$ 20
MedinCell [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment																		$ 3
Collaborative agreement milestone payments						$ 112					$ 105
MedinCell [Member] \| Research and Development Expense [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment																$ 5
MODAG [Member]
Noncash or Part Noncash Acquisitions [Line Items]
License agreement potential aggregate milestone payments amount										$ 20
MODAG [Member] \| Research and Development Expense [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment																			$ 10
Milestone Payment To Be Paid															$ 10
Subsequent Event [Member] \| Polpharma [Member] \| Research and Development Expense [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Milestone payment					$ 15